WO2025229495 - HETEROCYCLIC COMPOUND
National phase entry is expected:
Publication Number
WO/2025/229495
Publication Date
06.11.2025
International Application No.
PCT/IB2025/054397
International Filing Date
28.04.2025
Title **
[English]
HETEROCYCLIC COMPOUND
[French]
COMPOSÉ HÉTÉROCYCLIQUE
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
HATTORI, Yasushi
TOKUNAGA, Norihito
KIMURA, Eiji
IKEDA, Shuhei
PAWLICZEK, Martin Alexander
PIRA, Marilena
MIGUELEZ-RAMOS, Javier
MIYANOHANA, Yuhei
HOASHI, Yasutaka
KAJITA, Yuichi
ITO, Yoshiteru
KOIKE, Tatsuki
Priority Data
63/639,988
29.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3381 | |
| EPO | Filing, Examination, Granting | 19054 | |
| Japan | Filing, Examination, Granting | 2587 | |
| South Korea | Filing, Examination, Granting | 2951 | |
| USA | Filing, Examination, Granting | 8640 |
Total:
36,613
Contact Us
Abstract[English]
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): (I) wherein each symbol is as described in the description, or a salt thereof is useful as an agent for the prophylaxis or treatment of narcolepsy.[French]
La présente invention concerne un composé hétérocyclique ayant une activité agoniste des récepteurs de l'orexine de type 2. Un composé représenté par la formule (I), chaque symbole étant tel que défini dans la description, ou un sel de celui-ci est utile comme agent pour la prophylaxie ou le traitement de la narcolepsie.